Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy
2018 ◽
Vol 141
(2)
◽
pp. AB79
Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.
2021 ◽
Vol 39
(15_suppl)
◽
pp. 11512-11512